drugset / Trial / NCT02310464
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.
Timeline
- Start
- 2015-12-22
- Primary completion
- 2020-12-22
- Completion
- 2021-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OBI-821 | Other / unclassified | — | Subcutaneous |
| Subject | OBI-833 | Vaccine | — | Subcutaneous |